South Korea · Delayed Price · Currency is KRW CJ Bioscience Statistics
Total Valuation
CJ Bioscience has a market cap or net worth of KRW 50.37 billion. The enterprise value is 17.30 billion.
| Market Cap | 50.37B |
| Enterprise Value | 17.30B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CJ Bioscience has 13.07 million shares outstanding. The number of shares has increased by 16.13% in one year.
| Current Share Class | 13.07M |
| Shares Outstanding | 13.07M |
| Shares Change (YoY) | +16.13% |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | 3.54% |
| Owned by Institutions (%) | 0.01% |
| Float | 4.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13.70 |
| PB Ratio | 1.21 |
| P/TBV Ratio | 1.68 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.70 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.88, with a Debt / Equity ratio of 0.19.
| Current Ratio | 2.88 |
| Quick Ratio | 2.76 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.40 |
| Interest Coverage | -42.54 |
Financial Efficiency
Return on equity (ROE) is -41.76% and return on invested capital (ROIC) is -23.33%.
| Return on Equity (ROE) | -41.76% |
| Return on Assets (ROA) | -20.11% |
| Return on Invested Capital (ROIC) | -23.33% |
| Return on Capital Employed (ROCE) | -50.46% |
| Weighted Average Cost of Capital (WACC) | 6.97% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.05 |
| Inventory Turnover | 14.61 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -61.68% in the last 52 weeks. The beta is 0.54, so CJ Bioscience's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | -61.68% |
| 50-Day Moving Average | 3,901.30 |
| 200-Day Moving Average | 6,795.03 |
| Relative Strength Index (RSI) | 45.93 |
| Average Volume (20 Days) | 5,006 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CJ Bioscience had revenue of KRW 3.68 billion and -22.33 billion in losses. Loss per share was -1,709.28.
| Revenue | 3.68B |
| Gross Profit | 718.04M |
| Operating Income | -22.98B |
| Pretax Income | -22.33B |
| Net Income | -22.33B |
| EBITDA | -19.15B |
| EBIT | -22.98B |
| Loss Per Share | -1,709.28 |
Balance Sheet
The company has 40.95 billion in cash and 7.88 billion in debt, with a net cash position of 33.07 billion or 2,531.03 per share.
| Cash & Cash Equivalents | 40.95B |
| Total Debt | 7.88B |
| Net Cash | 33.07B |
| Net Cash Per Share | 2,531.03 |
| Equity (Book Value) | 41.75B |
| Book Value Per Share | 3,194.17 |
| Working Capital | 27.95B |
Cash Flow
In the last 12 months, operating cash flow was -19.77 billion and capital expenditures -19.76 million, giving a free cash flow of -19.79 billion.
| Operating Cash Flow | -19.77B |
| Capital Expenditures | -19.76M |
| Depreciation & Amortization | 3.82B |
| Net Borrowing | -1.10B |
| Free Cash Flow | -19.79B |
| FCF Per Share | -1,514.51 |
Margins
| Gross Margin | 19.53% |
| Operating Margin | -624.86% |
| Pretax Margin | -607.20% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CJ Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.13% |
| Shareholder Yield | -16.13% |
| Earnings Yield | -44.33% |
| FCF Yield | -39.29% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CJ Bioscience has an Altman Z-Score of -0.63 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.63 |
| Piotroski F-Score | 3 |